Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 20,074,000 | 16,747,000 | 14,240,000 | 12,682,000 | 11,888,000 |
| Cost of Goods | 6,221,000 | 5,257,000 | 4,345,000 | 3,956,000 | 3,711,000 |
| Gross Profit | 13,854,000 | 11,490,000 | 9,896,000 | 8,727,000 | 8,177,000 |
| Operating Expenses | 10,241,000 | 8,885,000 | 7,552,000 | 7,079,000 | 6,979,000 |
| Operating Income | 3,613,000 | 2,603,000 | 2,343,000 | 1,649,000 | 1,199,000 |
| Interest Expense | 349,000 | 305,000 | 265,000 | 470,000 | 341,000 |
| Other Income | 121,000 | -16,000 | -93,000 | -38,000 | 218,000 |
| Pre-tax Income | 3,385,000 | 2,282,000 | 1,985,000 | 1,141,000 | 1,076,000 |
| Income Tax | 493,000 | 436,000 | 393,000 | 443,000 | 36,000 |
| Net Income Continuous | 2,892,000 | 1,846,000 | 1,592,000 | 698,000 | 1,040,000 |
| Minority Interests | -6,000 | -8,000 | -1,000 | N/A | N/A |
| Net Income | $2,898,000 | $1,854,000 | $1,593,000 | $698,000 | $1,041,000 |
| EPS Basic Total Ops | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 |
| EPS Basic Continuous Ops | 1.95 | 1.25 | 1.10 | 0.49 | 0.73 |
| EPS Diluted Total Ops | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 |
| EPS Diluted Continuous Ops | 1.94 | 1.24 | 1.09 | 0.48 | 0.73 |
| EPS Diluted Before Non-Recurring Items | 3.06 | 2.51 | 2.05 | 1.71 | 1.63 |
| EBITDA(a) | $5,026,000 | $4,260,000 | $3,597,000 | $2,915,000 | $2,661,000 |